Reticulocyte mitochondrial retention increases reactive oxygen species and oxygen consumption in mouse models of sickle cell disease and phlebotomy-induced anemia
Its derived from a naturally occurring protein found in human stomach (gastric) juice, which is part of the reason researchers first became interested in it the body already produces a version of this compound as part of its natural protective processes
After one year, there was no evidence of any benefit on a wide range of cognitive and physical outcomes
However, no large-scale human clinical trials have confirmed these effects, so its use in people remains experimental and off-label
And thats whats seen in the clinical data: the waterfall plot for Daraxonrasib from the Phase 1b program is extremely impressive, with up to 35% overall response rate (vs
Coverage at NY Times, front page today and my input to that piece To view or add a comment, sign in This week, a seven-person FDA advisory committee will spend two days deciding the fate of peptides my patients have been asking about for over a year